title: Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival.
abstract: Graft-vs.-host disease (GVHD) is a major predictor of outcome following allogeneic bone marrow transplantation (BMT). For patients alive at day 100 after BMT, the presence or absence of chronic GVHD is one of the most important determinants of survival and quality of life. We wished to determine the effects on chronic GVHD of two regimens used for the prophylaxis of acute GVHD: cyclosporine, methotrexate, and prednisone (CSA/MTX/PSE) and cyclosporine and prednisone (CSA/PSE). One hundred forty-nine evaluable patients were entered into the acute GVHD study. As of 31 March 1997, 63 months after the last patient underwent BMT, the median survival time was 4.5 years (range 0.09-9.9). The incidence of chronic GVHD was independent of the prophylactic regimen (55 vs. 54%), and extensive chronic GVHD occurred in 25 and 24% of patients receiving CSA/MTX/PSE and CSA/PSE, respectively. Of note, the median Karnofsky performance status of both groups was 100% (range 70-100%), reflecting the low incidence of extensive chronic GVHD. Survival rates free of chronic GVHD were 52 vs. 42% (p = 0.29) for patients receiving CSA/MTX/PSE vs. CSA/PSE. The incidence of relapse was also similar in both groups of patients. These data suggest that the combinations of CSA/MTX/PSE and CSA/PSE result in comparable chronic GVHD-free survival without an increase in leukemic relapse.
authors.affiliation: Stanford University Medical Center Stanford, California, USA.
authors.forename: M
authors.initials: M
authors.lastname: Ross
authors.forename: G M
authors.initials: GM
authors.lastname: Schmidt
authors.forename: J C
authors.initials: JC
authors.lastname: Niland
authors.forename: M D
authors.initials: MD
authors.lastname: Amylon
authors.forename: A C
authors.initials: AC
authors.lastname: Dagis
authors.forename: G D
authors.initials: GD
authors.lastname: Long
authors.forename: A P
authors.initials: AP
authors.lastname: Nademanee
authors.forename: R S
authors.initials: RS
authors.lastname: Negrin
authors.forename: M R
authors.initials: MR
authors.lastname: O'Donnell
authors.forename: P M
authors.initials: PM
authors.lastname: Parker
authors.forename: E P
authors.initials: EP
authors.lastname: Smith
authors.forename: D S
authors.initials: DS
authors.lastname: Snyder
authors.forename: A S
authors.initials: AS
authors.lastname: Stein
authors.forename: R M
authors.initials: RM
authors.lastname: Wong
authors.forename: S J
authors.initials: SJ
authors.lastname: Forman
authors.forename: K G
authors.initials: KG
authors.lastname: Blume
authors.forename: N J
authors.initials: NJ
authors.lastname: Chao
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002423:Cause of Death; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D003141:Communicable Diseases / Q000209:etiology; D016572:Cyclosporine / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000401:mortality / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007223:Infant; D007938:Leukemia / Q000150:complications / Q000188:drug therapy / Q000628:therapy; D008137:Longitudinal Studies; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use*; D012008:Recurrence; D015996:Survival Rate; D014184:Transplantation, Homologous
chemical_list: D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011241:Prednisone; D008727:Methotrexate